Bioxyne Limited (AU:BXN) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Bioxyne Limited has announced a change in director Anthony Ho’s interests, with the acquisition of 5 million unlisted options approved by shareholders. The options have an exercise price of $0.02 and expire in December 2027. This change aligns with the company’s strategic decisions and reflects shareholder support.
For further insights into AU:BXN stock, check out TipRanks’ Stock Analysis page.